<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="29460">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02723188</url>
  </required_header>
  <id_info>
    <org_study_id>TASMC-13-TH-334</org_study_id>
    <nct_id>NCT02723188</nct_id>
  </id_info>
  <brief_title>Modulation of Fear Extinction Processes Using Transcranial Electrical Stimulation</brief_title>
  <official_title>Modulation of Fear Extinction Processes Using Transcranial Electrical Stimulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tel Aviv University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tel Aviv University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to examine the effects of transcranial electrical stimulation on
      processes associated with fear extinction in healthy humans.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Research links the processes of fear conditioning and extinction to the treatment of anxiety
      and stress-related disorders. Moreover, considerable translational research examines the
      neural correlates of these processes. However, virtually no research in humans manipulates
      neural correlates of these processes, which limits basic-clinical integration. The present
      study aimed to use transcranial electrical stimulation (tES) to modulate processes
      associated with fear extinction in order to assess the potential utility of tES in enhancing
      exposure-based treatment. To this end, healthy participants underwent a three-day fear
      conditioning and extinction paradigm. Participants were randomly assigned into 3 groups,
      differing in terms of tES applied during the extinction learning phase (Day 2) and targeting
      the medial prefrontal cortex: 1) direct current (DC) stimulation, aimed at enhancing
      extinction learning; 2) alternate current (AC) stimulation, aimed at interfering with
      reconsolidation of the fear memory activated during the extinction phase; and 3) sham
      stimulation. The outcome measures (outlined next) involve the assessment of extinction
      recall during a test phase (Day 3). Successful modulation of extinction learning by tES
      would be reflected in enhanced extinction recall.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Galvanic skin response (GSR)</measure>
    <time_frame>During three-day experimental task</time_frame>
    <description>Measured throughout task using 2 standard electrodes on fingers</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Self-reported fear rankings</measure>
    <time_frame>During three-day experimental task</time_frame>
    <description>Participants marked how fearful they are of stimuli used in task (1-7 scale)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Stress Related Disorder</condition>
  <condition>Anxiety</condition>
  <arm_group>
    <arm_group_label>Sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham electrical stimulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DC: Direct current</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Direct current electrical stimulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AC: Alternating current</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alternating current electrical stimulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham stimulation (1.5 milliampere,30 seconds)</intervention_name>
    <arm_group_label>Sham</arm_group_label>
    <other_name>DC Stimulator Plus (neuroConn, Germany), serial 0118</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DC stimulation (1.5 milliampere, 20 minutes)</intervention_name>
    <arm_group_label>DC: Direct current</arm_group_label>
    <other_name>DC Stimulator Plus (neuroConn, Germany), serial 0118</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AC stimulation (1.5 milliampere,1.5 Hertz frequency)</intervention_name>
    <arm_group_label>AC: Alternating current</arm_group_label>
    <other_name>DC Stimulator Plus (neuroConn, Germany), serial 0118</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Exclusion Criteria:

          -  Self-reported major psychiatric condition

          -  Screening specific for electrical stimulation (psychotropic medication, metal
             implants in head, epilepsy or seizure history)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>March 2016</verification_date>
  <lastchanged_date>March 29, 2016</lastchanged_date>
  <firstreceived_date>March 24, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tel Aviv University</investigator_affiliation>
    <investigator_full_name>Yair Bar-Haim</investigator_full_name>
    <investigator_title>Professor of Psychology</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
